Clark Peter E, Spiess Philippe E, Agarwal Neeraj, Bangs Rick, Boorjian Stephen A, Buyyounouski Mark K, Efstathiou Jason A, Flaig Thomas W, Friedlander Terence, Greenberg Richard E, Guru Khurshid A, Hahn Noah, Herr Harry W, Hoimes Christopher, Inman Brant A, Kader A Karim, Kibel Adam S, Kuzel Timothy M, Lele Subodh M, Meeks Joshua J, Michalski Jeff, Montgomery Jeffrey S, Pagliaro Lance C, Pal Sumanta K, Patterson Anthony, Petrylak Daniel, Plimack Elizabeth R, Pohar Kamal S, Porter Michael P, Sexton Wade J, Siefker-Radtke Arlene O, Sonpavde Guru, Tward Jonathan, Wile Geoffrey, Dwyer Mary A, Smith Courtney
From Vanderbilt-Ingram Cancer Center; Moffitt Cancer Center; Huntsman Cancer Institute at the University of Utah; Patient Advocate; Mayo Clinic Cancer Center; Stanford Cancer Institute; Massachusetts General Hospital Cancer Center; University of Colorado Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; Roswell Park Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Memorial Sloan Kettering Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred & Pamela Buffett Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Michigan Comprehensive Cancer Center; City of Hope Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Yale Cancer Center/Smilow Cancer Hospital; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Washington/Seattle Cancer Care Alliance; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; and National Comprehensive Cancer Network.
J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224. doi: 10.6004/jnccn.2016.0131.
These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.
这些美国国立综合癌症网络（NCCN）指南见解基于证据审查并结合专家组的专家意见，讨论了NCCN膀胱癌指南近期的主要更新内容。近期更新包括：（1）完善卡介苗膀胱内灌注的推荐；（2）强化围手术期全身化疗的推荐；（3）将免疫疗法纳入局部晚期或转移性疾病的二线治疗。这些NCCN指南见解进一步讨论了影响将这些推荐纳入临床实践的因素。
